Undoubtedly the big news of the month came from Merck spin-off Organon who finally launched as a global women’s health company. “For too long, for too many common conditions, such as heavy, painful, and irregular menstrual bleeding, incontinence and menopause and many others, women have been told to accept and normalize these conditions as a part of life,” said Sandy Milligan, Head of Organon Research & Development. “Organon’s mission is to change this. We believe this approach will be very successful — we hope to discover the ability to identify diseases earlier, the ability to modify the course of diseases or healthcare conditions and to ultimately, improve the quality of life for women at all stages.” Before Organon officially launched and spun out from Merck, they announced the acquisition of maternal health company Alydia Health. At launch the leadership team made it clear that the company plans to make similar acquisitions in the future.
Psychedelics x Women’s Health
The psychedelics space is expanding quickly and a handful of new companies having emerged over the past few years. Over the past few weeks two new psychedelics companies have now come on our radar who are exclusively focused on women’s health. Eastra Health will offer new solutions for under-addressed health conditions like menstrual pain or menopause through an innovative approach to drug discovery and a deep, holistic understanding of women’s health, biology, and specific needs. Aphrodite Health was founded by women, and focused on addressing women’s mental and physical health with psychedelic enhanced treatments, the company has developed a two pronged approach, with a long term drug discovery program to bring an FDA approved drug to market.
<
You’ve found some of our exclusive Inner Circle Content.
This article is only available for our Inner Circle Members. To read on:
